⚖️ Business Overview Key Metrics Total: 10/17 +2 ✅ Projected Operating Margin: 26.18% +0 ⚠️ Projected 5-Year Revenue CAGR: 6.13% +2 ✅✅ Last 5-Year ROIC: 26.15% +1 ✅ Estimated Cost of Capital: 6.92% (less than ROIC) +1 ✅ Last 5-Year Shares Outstanding CAGR: -3.00% -1 ❌ Projected 5-Year EPS CAGR: 7.94% (given the ease of manipulating earnings metrics, sub-10% growth warrants caution) +0 ⚠️ Projected 5-Year Dividend CAGR: 7.57% +1 ✅ Moody's Rating: A3 +2 ✅✅ Morningstar Moat: Wide +2 ✅✅ Morningstar Uncertainty: Low Wolters Kluwer in my opinion, despite the overall market narrative, is not that exposed to disruption by AI as some of its technological counterparts, given its business segments overall need for security, consistency and reliance. I see AI being used by the company to improves its operating margins over time and not depreciating them.Read more

As global travel settles into a more normalized rhythm, Booking Holdings (NASDAQ: BKNG) is no longer riding a simple rebound story. Instead, it’s navigating a more nuanced phase—one defined by traveler selectivity, budget awareness, and a growing preference for flexibility across how people move from place to place.Read more

Alphabet no longer looks like a bargain, and the market now wants proof the business can keep winning as search, video, cloud, and AI all shift at once. The upside case rests on a resilient ad-and-video core that funds heavy AI spending, a cloud business landing bigger long-term customer deals, and a self-driving unit that’s starting to look like a real business—not a science project.Read more

Microsoft is turning its everyday work tools, cloud services, and developer products into an AI-powered bundle that could keep customers locked in and spending more over time. See what could drive the next leg of growth—and what might slow it down, from regulation to the cost of running massive data centers.Read more

Catalysts Most Immediate Catalyst (1–2 Years): Weight-Loss Drug Boom: Novo Nordisk’s Wegovy (semaglutide) is dominating the obesity drug market , with demand outpacing supply. Obesity treatment is becoming a major new revenue stream.Read more

Nvidia’s next chapter depends on whether data centers keep racing to build more AI capacity—and whether Nvidia can stay the default choice for the chips and software that run it. The big question is what happens if rivals catch up, customers slow spending, or politics and power constraints make it harder to expand data centers.Read more

Demand for the most advanced chips keeps rising as artificial intelligence spreads into more products, and TSMC sits at the center of that supply chain with long-term partners. The catch is that building factories outside Taiwan and navigating currency swings and trade rules could squeeze profits even if sales keep climbing.Read more

NVIDIA rides a wave of AI spending as companies and governments build more powerful data centers and upgrade digital infrastructure. The big question is whether new chip launches and its broader “full system” approach keep customers hooked—despite export limits, supply bottlenecks, and big buyers trying to build their own chips.Read more

Update 27th Jan 2025 My original narrative was primarily based on Aswath Damodaran's Nvidia narrative and valuation. The recent news from DeepSeek further supports this narrative.Read more